Table 1 Select phase III clinical trials of ICI used in combination in RCC

From: Combination VEGFR/immune checkpoint inhibitor therapy: a promising new treatment for renal cell carcinoma

Clinical trial

Patients

Arms

Primary completion date

CheckMate 214

(NCT02231749)

1096

Nivolumab + ipilimumab (n = 550)

vs sunitinib (n = 546)

June 26, 2017

(reported)

IMmotion151

(NCT02420821)

915

Atezolizumab + bevacizumab (n = 454)

vs sunitinib (n = 461)

December 2017

(reported)

JAVELIN Renal 101

(NCT02684006)

830

(estimated)

Avelumab + axitinib

vs sunitinib

December 2, 2018

(estimated)

E7080-G000-307

(NCTNCT02811861)

734

(estimated)

Lenvatinib + pembrolizumab vs

Lenvatinib + everolimus vs sunitinib

January 15, 2020

(estimated)

KEYNOTE-426

(NCT02853331)

840

(estimated)

Pembrolizumab + axitinib

vs sunitinib

January 27, 2020

(estimated)

CheckMate 9ER

(NCT03141177)

1014

(estimated)

Nivolumab + cabozantinib

vs sunitinib

February 15, 2021

(estimated)